A Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD).

GlaxoSmithKline1 site in 1 country57 target enrollmentJanuary 2006

ConditionsSocial Anxiety Disorder

DrugsGW679769

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Social Anxiety Disorder
Sponsor: GlaxoSmithKline
Enrollment: 57
Locations: 1
Primary Endpoint: Change in images of the brain, when stimulated, after once daily dosing for 12 weeks with GW679769, comparator or placebo in subjects with SAD.
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

Registry

clinicaltrials.gov

Start Date

January 2006

End Date

TBD

Last Updated

17 years ago

Study Type

Interventional

Study Design

Parallel